Biogen Inc (NASDAQ: BIIB) flaunted slowness of -1.57% at $182.98, before settling in for the price of $185.90 at the close. Taking a more long-term approach, BIIB posted a 52-week range of $181.31-$268.30.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was -4.53%. Meanwhile, its Annual Earning per share during the time was -18.05%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 9.84%. This publicly-traded company’s shares outstanding now amounts to $144.90 million, simultaneously with a float of $144.53 million. The organization now has a market capitalization sitting at $26.65 billion.
Biogen Inc (BIIB) Ownership Facts and Figures
Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Biogen Inc industry. Biogen Inc’s current insider ownership accounts for 0.77%, in contrast to 89.31% institutional ownership. According to the most recent insider trade that took place on Sep 03 ’24, this organization’s Head of Development sold 431 shares at the rate of 204.22, making the entire transaction reach 88,019 in total value, affecting insider ownership by 5,316.
Biogen Inc (BIIB) Earnings and Revenue Records
Biogen Inc’s EPS increase for this current 12-month fiscal period is 9.84% and is forecasted to reach 17.20 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 6.00% through the next 5 years, which can be compared against the -18.05% growth it accomplished over the previous five years trading on the market.
Biogen Inc (NASDAQ: BIIB) Trading Performance Indicators
Let’s observe the current performance indicators for Biogen Inc (BIIB). It’s Quick Ratio in the last reported quarter now stands at 1.48. The Stock has managed to achieve an average true range (ATR) of 4.06. Alongside those numbers, its PE Ratio stands at $23.05, and its Beta score is -0.08. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 2.87. Similarly, its price to free cash flow for trailing twelve months is now 17.03.
In the same vein, BIIB’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 7.94, a figure that is expected to reach 3.77 in the next quarter, and analysts are predicting that it will be 17.20 at the market close of one year from today.
